Prothena traded at $9.21 this Friday March 13th, decreasing $0.10 or 1.07 percent since the previous trading session. Looking back, over the last four weeks, Prothena lost 2.79 percent. Over the last 12 months, its price fell by 32.97 percent. Looking ahead, we forecast Prothena to be priced at 8.93 by the end of this quarter and at 8.15 in one year, according to Trading Economics global macro models projections and analysts expectations.
Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.